US Bancorp DE Buys 4,656 Shares of Astrana Health, Inc. (NASDAQ:ASTH)

US Bancorp DE boosted its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 3,880.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,776 shares of the company’s stock after purchasing an additional 4,656 shares during the period. US Bancorp DE’s holdings in Astrana Health were worth $151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC acquired a new stake in Astrana Health in the third quarter valued at $1,164,000. Royce & Associates LP acquired a new stake in Astrana Health in the third quarter valued at $6,661,000. Amalgamated Bank acquired a new stake in Astrana Health in the third quarter valued at $713,000. Principal Financial Group Inc. acquired a new stake in Astrana Health in the third quarter valued at $13,383,000. Finally, Loomis Sayles & Co. L P acquired a new stake in Astrana Health in the third quarter valued at $30,251,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ASTH has been the subject of a number of recent research reports. Bank of America decreased their price objective on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Robert W. Baird decreased their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Macquarie upgraded Astrana Health to a “hold” rating in a report on Monday, December 16th. Truist Financial decreased their price target on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a report on Monday, January 13th. Finally, Stifel Nicolaus decreased their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Astrana Health presently has an average rating of “Moderate Buy” and an average price target of $56.83.

Astrana Health Price Performance

ASTH stock opened at $29.34 on Friday. The stock has a market capitalization of $1.65 billion, a PE ratio of 22.57, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The company’s 50-day moving average is $33.96 and its 200-day moving average is $43.10. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a 1 year low of $23.12 and a 1 year high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The company had revenue of $665.21 million for the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. Equities research analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.